Intensity Therapeutics, Inc.
INTS
$3.70
-$0.04-1.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.81% | -25.28% | -17.96% | 7.75% | 72.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.81% | -28.08% | -17.78% | 29.04% | 99.39% |
| Operating Income | 27.81% | 28.08% | 17.78% | -29.04% | -99.39% |
| Income Before Tax | 28.66% | 27.82% | 16.56% | -8.74% | -54.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.66% | 27.82% | 16.56% | -8.74% | -54.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.66% | 27.82% | 16.56% | -8.74% | -54.37% |
| EBIT | 27.81% | 28.08% | 17.78% | -29.04% | -99.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 60.00% | 46.08% | 24.45% | 51.12% | 47.17% |
| Normalized Basic EPS | 60.00% | 46.08% | 24.45% | 7.63% | 2.35% |
| EPS Diluted | 55.53% | 46.08% | 24.45% | 51.12% | 47.17% |
| Normalized Diluted EPS | 60.00% | 46.08% | 24.45% | 7.63% | 2.35% |
| Average Basic Shares Outstanding | 143.27% | 66.35% | 13.49% | 27.85% | 61.93% |
| Average Diluted Shares Outstanding | 143.27% | 66.35% | 13.49% | 27.85% | 61.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |